Bioray Biotech Co (ROCO:7561) Shares Outstanding (EOP): 29.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7561 Bioray Biotech Co Ltd ROCO:7561
83 GF Score
Price NT$18.90
GF Value NT$29.51
Valuation Significantly Undervalued
View Full Analysis

What is Bioray Biotech Co Shares Outstanding (EOP)?

Bioray Biotech Co ROCO:7561 83 Shares Outstanding (EOP) is 29.6 Mil as of Dec. 2025. GuruFocus rates ROCO:7561 with a GF Score™ of 83/100 and a GF Value™ of NT$29.51 (Significantly Undervalued).

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Bioray Biotech Co's shares outstanding for the quarter that ended in Dec. 2025 was 29.6 Mil.

Bioray Biotech Co's quarterly shares outstanding stayed the same from Jun. 2025 (29.6 Mil) to Dec. 2025 (29.6 Mil).

Bioray Biotech Co's annual shares outstanding stayed the same from Dec. 2024 (29.6 Mil) to Dec. 2025 (29.6 Mil).


Bioray Biotech Co  (ROCO:7561) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Bioray Biotech Co Shares Outstanding (EOP) Related Terms


Bioray Biotech Co Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Bioray Biotech Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioray Biotech Co Shares Outstanding (EOP) Chart

Bioray Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 27.41 30.09 30.09 29.59 29.59

Bioray Biotech Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.09 30.09 29.59 29.59 29.59

ROCO:7561 vs ZTS, UTHR: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioray Biotech Co Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Bioray Biotech Co's Shares Outstanding (EOP) falls into.


ROCO:7561
83GF Score
Bioray Biotech Co Ltd ROCO:7561
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioray Biotech Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 29.6 Mil mean?
Bioray Biotech Co (ROCO:7561) has a Shares Outstanding (EOP) of 29.6 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Bioray Biotech Co and its competitors.
Is Bioray Biotech Co's Shares Outstanding (EOP) too high?
Bioray Biotech Co's current Shares Outstanding (EOP) is 29.6 Mil. Overall, Bioray Biotech Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's Shares Outstanding (EOP) compare to ZTS and UTHR?
Bioray Biotech Co's Shares Outstanding (EOP) of 29.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Bioray Biotech Co and its competitors. Bioray Biotech Co's current Shares Outstanding (EOP) is 29.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.51, compared to a current price of NT$18.90 — trading 36% below its estimated fair value. The current Shares Outstanding (EOP) is 29.6 Mil. Bioray Biotech Co's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current Shares Outstanding (EOP) is 29.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?

Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued. The current stock price of NT$18.90 is trading 36% below its estimated GF Value™ of NT$29.51. GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.

Key valuation signals for ROCO:7561:

  • Shares Outstanding (EOP): 29.6 Mil
  • GF Value™: NT$29.51 vs. price of NT$18.90 (36% below fair value)
  • GF Score™: 83/100

No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioray Biotech Co Business Description

Address No. 1, Dali 2nd Road, Southern Science Park, Shanhua District, Tainan, TWN, 90846
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
83GF Score

Get the complete analysis for ROCO:7561

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.90
Price
NT$29.51
GF Value